申请人:Kobashi Seiichi
公开号:US20120184587A1
公开(公告)日:2012-07-19
Disclosed are a novel compound and a pharmaceutical product, each having a remarkable uricosuric effect. Specifically disclosed are: a novel phenol derivative represented by general formula (1) that is shown in FIG.
1
; a pharmaceutically acceptable salt thereof; a hydrate of the derivative or the salt; and a solvate of the derivative or the salt. (In the formula, R
1
and R
2
may be the same or different and each represents a lower alkyl group, a lower alkenyl group, a lower alkynyl group, a lower alkoxy group, a haloalkyl group, a haloalkoxy group, an alkylsulfanyl group, an alkylsulfinyl group, an alkylsulfonyl group, a lower alkyl-substituted carbamoyl group, a saturated nitrogen-containing heterocyclic N-carbonyl group, a halogen atom, a cyano group or a hydrogen atom; R
3
represents a lower alkyl group, a haloalkyl group, a halogen atom, a hydroxy group or a hydrogen atom; and X represents a sulfur atom, an —S(═O)— group or an —S(═O)
2
— group.)
揭示了一种新型化合物和一种药物产品,每种都具有显著的利尿酸效果。具体揭示了:一种新型酚衍生物,其通式(1)如图1所示;其药学上可接受的盐;该衍生物或盐的水合物;以及该衍生物或盐的溶剂化合物。(在该式中,R1和R2可以相同也可以不同,每个代表较低的烷基基团、较低的烯基基团、较低的炔基基团、较低的烷氧基团、卤代烷基基团、卤代烷氧基团、烷基硫基团、烷基亚硫基团、烷基磺基团、较低烷基取代的氨基甲酰基团、饱和的含氮杂环N-羰基团、卤素原子、氰基或氢原子;R3代表较低的烷基基团、卤代烷基基团、卤素原子、羟基或氢原子;X代表硫原子、—S(═O)—基团或—S(═O)2—基团。)